Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Worldwide Offices
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

GI MAP Test Launches Cyclospora Guidance Service for Customers With a Detected Test Result


News provided by

GI MAP

20 Aug, 2026, 20:49 GMT

Share this article

Share toX

Share this article

Share toX

AUGUSTINE, Fla., Aug. 20, 2026 /PRNewswire/ -- GI MAP Test, a service that provides access to the GI-MAP™ comprehensive stool test in the United States and Canada, has launched a guidance resource for customers whose test result detects the intestinal parasite Cyclospora. The company announced the service on August 5, 2026.

The resource is provided at no additional cost to eligible customers. It is sent by email together with the customer's test results, and only when the result detects Cyclospora. It is not sent at the time the test is purchased.

Continue Reading
This image opens in the lightbox
GI MAP

What the Service Provides

The guidance resource is educational. It was written to answer the practical questions a person may have in the days immediately after a parasite is detected in a stool test.

The resource explains what Cyclospora is and what a detected result on the panel may mean. It describes common sources of contamination so customers can reduce the risk of a repeat exposure. It also identifies symptoms that may require urgent medical attention rather than waiting for a routine appointment, and it sets general expectations for digestive recovery, including why symptoms can continue for a period after an infection has been treated.

The company states clearly what the resource does not do. It does not provide prescription medication instructions or dosing. It does not diagnose a condition, interpret symptoms in place of a medical evaluation, or offer any self-treatment pathway. Customers are directed to a licensed clinician for evaluation and treatment.

"A laboratory result is only useful if the person holding it knows what to do next," said Madison Ordway, FDN-P, the Functional Diagnostic Nutrition Practitioner who reviews the company's educational content. "The purpose of this resource is to help people arrive at their appointment prepared, and to explain why recovery can take time even after treatment is complete. It is not a replacement for a prescriber."

How the Test Detects the Parasite

The GI-MAP™ is an at-home stool test analyzed by Diagnostic Solutions Laboratory, a CLIA-certified laboratory in the United States. It uses quantitative real-time PCR (qPCR) DNA analysis to detect and measure more than 85 gut targets from a single sample. These include bacterial, parasitic and viral pathogens, fungi and yeast, commensal bacteria, and markers of digestion, inflammation and immune function.

Cyclospora is included in the protozoan parasite section of the panel. Because qPCR identifies specific DNA sequences rather than relying on culture or microscopy, it can detect organisms that are present in small numbers. Results are returned in approximately 14 to 16 days after the laboratory receives the sample and are reviewed by a practitioner.

Why the Company Created the Service

Public health authorities, including the U.S. Centers for Disease Control and Prevention, describe Cyclospora as a microscopic single-celled parasite that infects the lining of the small intestine. People become infected by consuming contaminated food or water. Its symptoms, including watery diarrhea, loss of appetite, and fatigue, resemble many other digestive infections, so laboratory testing is needed to identify the organism, and treatment requires prescription therapy ordered by a qualified clinician.

According to the company, that combination is what created the need for the service. A customer can receive a detected result at home, without a clinician present to explain it, and then face a wait before an appointment. The resource is intended to fill that gap with plain-language information and to make the eventual appointment more productive.

Who Is Eligible

The guidance resource is available to customers who ordered their GI-MAP™ test through GI MAP Test and received a result detecting Cyclospora. It is included as part of the service, and there is nothing further to purchase.

Customers who ordered their test through another practitioner, clinic, distributor or laboratory are not covered by the service and are advised to return to the provider who placed their order. The company also advises anyone who is acutely unwell not to wait for the resource, and to contact a clinician or seek urgent medical care.

Due to state laboratory regulations, the GI-MAP™ test cannot be processed for residents of New York, New Jersey, or Rhode Island.

The announcement and further information are available at https://gimaptest.com/en/cyclospora/

About GI MAP Test

GI MAP Test provides access to the GI-MAP™ comprehensive stool test for customers in the United States and Canada, including the practitioner order required for laboratory testing. The test is analyzed by Diagnostic Solutions Laboratory using qPCR DNA technology and reports more than 85 gut biomarkers from a single at-home sample. Educational content published by the company is reviewed by Madison Ordway, FDN-P, a Functional Diagnostic Nutrition Practitioner.

GI-MAP™ is a trademark of Diagnostic Solutions Laboratory, LLC. GI MAP Test works with authorized providers and is not affiliated with or endorsed by Diagnostic Solutions Laboratory.

This announcement is provided for general educational purposes only. It is not medical advice and is not intended to diagnose, treat, cure, or prevent any disease. Test results, symptoms, and treatment should be discussed with a qualified healthcare professional.

Media Contact

Media Contact: Madison Ordway, FDN-P
Company: Real Health Diagnostics Inc. (gimaptest.com)
Email: hello@gimaptest.com
Phone number:
672-969-1200
Website: GI MAP Test

Disclaimer: This article is intended for general informational and educational purposes only. It does not provide medical advice, diagnosis, treatment, laboratory interpretation, or prescription guidance, and it should not be relied upon as a substitute for consultation with a qualified healthcare professional. Any discussion of GI-MAP™ testing, qPCR analysis, Cyclospora, stool test results, digestive symptoms, parasites, recovery, or related health information is provided for general context only. Test results, symptoms, treatment options, and follow-up care should be reviewed with a licensed clinician or other qualified healthcare provider. Anyone experiencing severe, worsening, or urgent symptoms should seek prompt medical attention. References to GI MAP Test, Diagnostic Solutions Laboratory, Madison Ordway, FDN-P, service details, eligibility, and related information are based on provided or publicly available materials and should be independently reviewed by readers.

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content

About

  • About PR Newswire
  • About Cision
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • PR Newswire Amplify™
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.